Antiplatelet Therapy in Atherothrombotic Cardiovascular Diseases for Primary and Secondary Prevention: A Focus on Old and New Antiplatelet Agents

Author(s): Burak Pamukcu, Kurt Huber, Gregory Y.H. Lip

Journal Name: Current Pharmaceutical Design

Volume 18 , Issue 6 , 2012

Become EABM
Become Reviewer


Aspirin has long been the mainstay of primary and secondary prevention against myocardial infarction and ischemic cerebrovascular events. However, the incremental value of aspirin for primary prevention has recently been subject to debate given data from recent large clinical trials, as the net clinical benefit is small. In secondary prevention, aspirin is still strongly recommended.

Efforts in obtaining more efficient antiplatelet agents and to reduce cardiovascular morbidity and mortality have led to the development of new adenosine diphosphate (ADP) receptor antagonists, which are superior to clopidogrel. New generation antiplatelet drugs i.e. prasugrel and ticagrelor aim to reduce atherothrombotic events, mortality and stent thrombosis, as well as overcome low- or non-response to clopidogrel. Further agents with antiplatelet properties are being investigated at present.

This overview aims to give insights into the rapidly changing field of antiplatelet strategies in cardiovascular diseases.

Keywords: Atherothrombosis, cardiovascular disease, primary prevention, secondary prevention, novel antithrombotics, acetyl salicylic acid, adenosine diphosphate (ADP), infarction, ischemic cerebrovascular, clopidogrel

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [850 - 860]
Pages: 11
DOI: 10.2174/138161212799277716
Price: $65

Article Metrics

PDF: 14